Hoth Therapeutics Provides Comprehensive Update on Pipeline Progress, Including Advancements in HT-001 and HT-KIT Trials, and Launch of GDNF-Based Metabolic Program

Hoth Therapeutics has provided a comprehensive update on its therapeutic pipeline, highlighting clinical progress, orphan-designated HT-KIT, advancing HT-001 Phase 2, and a new GDNF metabolic program. The company has reported strong safety profiles and consistent improvement trends in rash severity and pruritus for HT-001. HT-KIT has received FDA orphan drug designation and is progressing through IND-enabling activities. HT-ALZ is advancing through GLP and PK development, and the GDNF-based weight-loss and metabolic program has initiated study preparations with the Atlanta VA Medical Center.